""Most importantly, when you look at the global need, we expect that there are more than one billion people across the globe that are suffering from obesity; there is no way that we can meet those demands with injectable treatments today.""
""Orforglipron will likely unlock a much wider market, bringing the benefits of groundbreaking weight-loss drugs to people who can't, or don't want to, use injections.""
Eli Lilly's Phase 3 study results for orforglipron, a new GLP-1 pill for weight loss and diabetes, show promising outcomes. This pill is similar to well-known injectables like Ozempic but more accessible due to its oral format. It targets a significant global obesity crisis, with Lilly aiming for FDA approval by late 2025. The pill promises to reach a broader audience by providing a weight-loss solution for individuals averse to injections, thereby potentially revolutionizing the treatment landscape.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]